D. Boral Capital upgraded Can-Fite BioPharma to Buy from Hold with a $7 price target. The firm, which notes that its prior downgrade was driven primarily by the reverse split dynamic rather than deterioration in the company's science or clinical programs, believes sufficient time has now passed since the company's reverse stock split and associated technical selling pressure, allowing investors to refocus on the underlying clinical pipeline and emerging oncology opportunity.
